| Valley Medical Supplies | |
| 173 E Springbrook Rd, Ste A, Broadway, Virginia 22815 | |
| (540) 901-2782 |
| Name | Valley Medical Supplies |
|---|---|
| Organization Name | Valley Medical Supplies, Llc |
| Location | 173 E Springbrook Rd, Ste A, Broadway, Virginia 22815 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (540) 901-2782 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Lung cancer is one of the developed world's biggest cancer killers; it causes 33,000 deaths each year in Britain, claims the lives of 7,000 Australians each year and in 2007 it is estimated that 160,390 Americans will die from the disease.
By seeing what substances and molecules affect the development of our diseases, we can develop drugs that prevent or cure diseases. In her dissertation at Kalmar University in Sweden, Ann Novotny has found that the signal molecule acetylcholine (ACh) is important for the progress of cancer of the large intestine and colon, knowledge that is important to factor in when developing drugs that block the effects of Ach on tumor cells.
A prominent problem in AIDS is a form of dementia that robs one's ability to concentrate and perform normal movements.
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.
› Verified 9 days ago
| NPI Number | 1346713054 |
| Organization Name | VALLEY MEDICAL SUPPLIES, LLC |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 173 E Springbrook Rd, Suite A, Broadway, VA 22815 |
| Phone Number | 540-214-6294 |
News Archive
Lung cancer is one of the developed world's biggest cancer killers; it causes 33,000 deaths each year in Britain, claims the lives of 7,000 Australians each year and in 2007 it is estimated that 160,390 Americans will die from the disease.
By seeing what substances and molecules affect the development of our diseases, we can develop drugs that prevent or cure diseases. In her dissertation at Kalmar University in Sweden, Ann Novotny has found that the signal molecule acetylcholine (ACh) is important for the progress of cancer of the large intestine and colon, knowledge that is important to factor in when developing drugs that block the effects of Ach on tumor cells.
A prominent problem in AIDS is a form of dementia that robs one's ability to concentrate and perform normal movements.
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.
› Verified 9 days ago
News Archive
Lung cancer is one of the developed world's biggest cancer killers; it causes 33,000 deaths each year in Britain, claims the lives of 7,000 Australians each year and in 2007 it is estimated that 160,390 Americans will die from the disease.
By seeing what substances and molecules affect the development of our diseases, we can develop drugs that prevent or cure diseases. In her dissertation at Kalmar University in Sweden, Ann Novotny has found that the signal molecule acetylcholine (ACh) is important for the progress of cancer of the large intestine and colon, knowledge that is important to factor in when developing drugs that block the effects of Ach on tumor cells.
A prominent problem in AIDS is a form of dementia that robs one's ability to concentrate and perform normal movements.
Celtaxsys, Inc., a clinical stage pharmaceutical development company focusing on anti-inflammatory therapeutics, including those with rare and orphan inflammatory disease indications, announced today that it has gained clearance from the U.S. Food and Drug Administration to begin a Phase 2 clinical trial of its flagship drug candidate, acebilustat (CTX-4430), in adult CF patients in the US.
› Verified 9 days ago
Valley Medical Supplies Type: Durable Medical Equipment & Medical Supplies Supplier Location: 173 E Springbrook Rd, Broadway, Virginia 22815 Phone: (540) 901-2782 |